

Curriculum vitae**Florian Lordick, M.D., PhD**

Working address: University Cancer Center Leipzig (UCCL)
at University Hospital Leipzig, Germany

Position: Director of the University Cancer Center
Chairman of the Hematology and Oncology Department
Full Professor of Oncology

Medical training: 1987-1993 Regensburg, Munich and Lausanne

Internship/Residency: 1994-2002 Internal Medicine and Hematology/Oncology
Technical University of Munich, Germany

Senior physician: 4/02-7/07 Hematology and Oncology
Technical University of Munich, Germany
7/07-6/09 National Center for Tumor Diseases (NCT)
University of Heidelberg, Germany

Director: 6/09-9/12 Director of Hematology and Medical Oncology
Klinikum Braunschweig, Germany
Since 9/2012 Director of the University Cancer Center (UCCL),
University of Leipzig, Germany
Since 10/2018 Director of the Department of Hematology, Cell
Therapy, Oncology and Hemostaseology
University Hospital Leipzig, Germany

Visiting Periods: 6/2005 Memorial Sloan Kettering Cancer Center, NY

Qualifications/Degrees: 7/1994 Degree „Doctor medicinae“ (M.D.)
5/2000 Degree in „Internal Medicine“
5/2003 Degree in “Hematology and Medical Oncology”
9/2003 European Certification in Medical Oncology
11/2006 Habilitation (Ph.D. equivalent)
4/2010 Appointment as Associate Professor, Hannover
8/2012 Appointment as Full Professor, Leipzig

Professional societies: 1/97 German Society of Internal Medicine (DGIM)
4/01 European Society for Medical Oncology (ESMO)
9/01 German Society of Hemato-Oncology (GSHO)
5/02 American Society of Clinical Oncology (ASCO)
2/02 European Organization of Research and
Treatment of Cancer (EORTC)
8/04 German Cancer Society (DKG)
6/13 International Gastric Cancer Association (IGCA)
4/15 German Society for Gastroenterology (DGVS)

Leadership positions: 09/04-07/08 Chairman of the “Esophageal and
Gastric Cancer Working Group” of the AIO /
German Cancer Society
11/07-11/13 Board of Directors of the AIO
03/08-12/14 Chairman of the Gastric and Esophageal Cancer
Task Force of the EORTC

03/12-02/18	Chairman of the Palliative Care working group of the German Cancer Society
04/14-04/18	Executive Board of the German Society of Internal Medicine (DGIM)
Since 06/14	Board of Directors and Secretary of the German Cancer Society (DKG)
01/15-12/17	Secretary of the EORTC GI Tract Cancer Group
Since 01/17	Coordinator of the Gastrointestinal Tract Cancer Faculty of the European Society of Medical Oncology (ESMO)
Since 05/17	Nomination into the European School of Oncology (ESO) Core Faculty
Since 01/18	Chairman of the EORTC GI Tract Cancer Group
Since 01/19	ESMO representative of the ESMO/ASCO Global Curriculum Working Group
Since 05/19	President of the International Gastric Cancer Association (IGCA)

Scientific focus: Gastrointestinal Oncology
Multimodality and personalized cancer care
Drug resistance in ex-vivo models and imaging
Palliative care

Scientific Advisor and Reviewer: Reviewer for scientific medical journals: including
N Engl J Med, Lancet, Lancet Oncology, J Clin
Onc, JAMA Oncology, Clin Canc Res, Eur J
Cancer, Brit J Cancer

Reviewer for the German Cancer Aid (DKH),
Deutsche Forschungsgemeinschaft (DFG),
UK Medical Research Council (UK-MRC),
Swiss Cancer Research Working Group (SAKK);
French National Cancer Institute

Editor-in-chief: Forum (Springer)

Editor: Gastric Cancer (Springer)

Section editor: Der Onkologe (Springer)

Editorial Board Member: Annals of Oncology (Oxford Press)
Cancer Treatment Reviews (Elsevier)
Journal of Radiation Oncology Physics (Springer)
Digestion (Karger)
Magazine European Medical Oncology (Springer)

Publications: > 300 peer-reviewed articles and text book
chapters



Prof. Dr. med. Florian Lordick

Publications list - Florian Lordick

21531 citations – h-index 67 – i10-index 205
(according to google scholar accessed on 26th May 2019)

Original papers

1. **Lordick F**, Hauck RW, Senekowitsch R, Emslander HP. Atrial Natriuretic Peptide in Acute Hypoxia-Exposed Healthy Subjects and in Hypoxaemic Patients. *Eur Respir J* 1995; 8: 216-221
2. **Lordick F**, Gündel H, von Schilling C, Würschmidt F, Leps B, Sendler A, Schüßler J, Brandl T, Peschel C und Sellschopp A. Structured Educational Group Interventions in Cancer Patients: A Prospective Study to Evaluate its Implementation and Effectiveness at a German University Hospital. *Med Klin* 2002; 97: 449-454
3. **Lordick F**, Hentrich M, Decker T, Hennig M, Pohlmann H, Hartenstein R, Peschel C. Ultrasound Screening for Internal Jugular Vein Thrombosis Aids the Detection of Central Venous Catheter-Related Infections in Patients with Haemato-Oncological Diseases: a Prospective Observational Study. *Brit J Haematol* 2003; 120: 1073-1078
4. **Lordick F**, von Schilling C, Bernhard H, Hennig M, Bredenkamp R and Peschel C. Phase II Trial of Irinotecan Plus Docetaxel in Cisplatin-Pretreated Relapsed or Refractory Oesophageal Cancer. *Br J Cancer* 2003; 89: 630-633
5. Gündel H, **Lordick F**, Brandl T, Würschmidt F, Schussler J, Leps B, Sendler A, Mert E, Pouget-Schors D, von Schilling C, Peschel C, Sellschopp A. Interdisciplinary Psychoeducational Intervention by Oncologists Proved Helpful for Cancer Patients. *Z Psychosom Med Psychother* 2003; 49: 246-261
6. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, Stein H, **Lordick F**, Link T, Schwaiger M, Siewert JR, Weber WA. Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial. *J Clin Oncol* 2003; 21: 4604-4610
7. Wieder AH, Brücher BLDM, Zimmermann F, Becker K, **Lordick F**, Schwaiger M, Siewert JR, Stein HJ, Fink U, Weber WA. Time Course of Tumor Metabolic Activity During Radiochemotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment. *J Clin Oncol* 2004; 22: 900-908
8. Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thödtmann J, **Lordick F**. The Impact of Delayed Chemotherapy-Induced Nausea and Vomiting on Patients, Health Resource Utilization and Costs in German Cancer Centers. *Ann Oncol* 2004; 15: 526-536
9. Voelter V, Schuhmacher C, Busch R, Peschel C, Siewert JR, **Lordick F**. Therapy-Related Anemia in Patients Receiving Neoadjuvant Chemotherapy in Locally Advanced Esophago-Gastric Cancer. *Ann Thorac Surg* 2004; 78: 1037-1041
10. Napieralski R, Ott K, Kremer M, Specht K, Vogelsang H, Becker K, Müller M, **Lordick F**, Fink U, Siewert JR, Höfler H, Keller G. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-

treated gastric cancer patients. Clin Cancer Res 2005; 15:3025-3031

11. Lorenzen S, Duyster J, Lersch C, von Delius S, Hennig M, Bredenkamp R, Peschel C and **Lordick F**. Capecitabine plus docetaxel every three weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Brit J Cancer 2005; 92: 2129-2133
12. **Lordick F**, Lorenzen S, Stollfuss J, Vehling-Kaiser U, Kullmann F, Hentrich M, Zumschlinge R, Dietzfelbinger H, Thoedtman J, Hennig M, Seroneit T, Bredenkamp R, Duyster J, Peschel C. Phase II Study of Weekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin (FUFOX) in First Line Metastatic Gastric Cancer. Brit J Cancer 2005; 93: 190-194
13. Bubnoff N, Gorantla SHP, Kancha RK, **Lordick F**, Peschel C, Duyster J. The systemic mastocytosis-specific activating cKIT mutation D186V can be inhibited by the kinase inhibitor AMN107. Leukemia 2005; 19: 1670-1671
14. Wieder H, Beer A, **Lordick F**, Ott K, Fischer M, Rummeny EJ, Ziegler S, Siewert JR, Schwaiger M, Weber WA. Comparison of Changes in Tumor Metabolic Activity and Tumor Size During Chemotherapy of Adenocarcinomas of the Esophagus. J Nucl Med 2005; 46: 2029-2034
15. Hochster H, Kettner E, Kröning H, Becker K, **Lordick F**, Ramanathan RK, Macdonald J, Hong S, John W, Schmoll HJ. Phase I/II Dose-Escalation Study of Pemetrexed plus Irinotecan in Patients with Advanced Colorectal Cancer. Clin Colorectal Cancer 2005; 5: 257-262
16. Miething C, Feihl S, Mugler C, Grundler R, von Bubnoff N, **Lordick F**, Peschel C, Duyster J. The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 2006; 20: 650-657
17. **Lordick F**, Geinitz H, Theisen J, Sarbia M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: a report of three cases. Int J Radiation Oncol Biol Physics 2006; 46: 1295-1298
18. Beer AJ, Wieder HA, **Lordick F**, Ott K, Fischer M, Becker K, Stollfuss J, Weber WA, Rummeny EJ. Adenocarcinomas of the Esophagogastric Junction: MDCT for Evaluation of Early Response to Neoadjuvant Chemotherapy. Radiology 2006; 239: 472-480
19. Bruecher BLDM, Becker K, **Lordick F**, Fink U, Sarbia M, Stein HJ, Busch R, Zimmermann F, Molls M, Hoefler H, Siewert JR. The clinical impact of histopathological response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006; 106: 2119-2127
20. Apro M, Grunberg SM, Manikhas GM, Alexander FM, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, **Lordick F**, Macciocchi A. A Phase III Double-Blind Randomized Trial of Palonosetron Compared With Ondansetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) Following Highly Emetogenic Chemotherapy. Ann Oncol 2006; 17: 1441-1449
21. Abbrederis K, Bassermann F, Schuhmacher C, Voelter V, Busch R, Rothling N, Sandler A, Siewert JR, Peschel C, **Lordick F**. Erythropoietin-alfa for the management during neoadjuvant chemotherapy for locally advanced oesophagogastric adenocarcinoma. Ann Thorac Surg 2006; 82: 293-297.

22. Ott K, Vogelsang H, Marton N, Becker K, **Lordick F**, Kobl M, Schuhmacher C, Novotny A, Mueller J, Fink U, Ulm K, Siewert JR, Hofler H, Keller G. The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. *Int J Cancer*. 2006; 119: 2885-2894.
23. Ott K, Weber WA, **Lordick F**, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR. Metabolic imaging predicts response, survival and recurrence in adenocarcinomas of the esophagogastric junction (AEG) in a prospective trial. *J Clin Oncol* 2006; 24: 4692-4698
24. Witzig R, Schönberger B, Fink U, Busch R, Guendel H, Sendler A, Peschel C, Siewert JR, **Lordick F**. Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma. *Endoscopy* 2006; 38: 1122-1126
25. **Lordick F**, Ehlken B, Ihbe-Heffinger A, Berger K, Krobot KJ, Pellissier J, Davies G, Deuson R. Health outcomes and cost-effectiveness of aprepitant in patients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. *Eur J Cancer* 2007; 42: 299-307
26. Rodel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, Furst A, Schwella N, Bieker M, Hellmich G, Ewald H, Haier J, **Lordick F**, Flentje M, Sulberg H, Hohenberger W, Sauer R. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. *J Clin Oncol* 2007; 25: 110-7
27. Wieder HA, Geinitz H, Rosenberg R, **Lordick F**, Becker K, Stahl A, Rummeny E, Siewert JR, Schwaiger M, Stollfuss J. PET imaging with [(18)F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. *Eur J Nucl Med Mol Imaging* 2007; 34: 878-883
28. Boeck S, Weigang-Kohler K, Fuchs M, Kettner E, Quietzsch D, Trojan J, Stotzer O, Zeuzem S, **Lordick F**, Kohne CH, Kroning H, Steinmetz T, Depenbrock H, Heinemann V. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. *Ann Oncol* 2007; 18: 745-51
29. Schuhmacher C, **Lordick F**, Bumm R, Tepe J, Siewert JR. Good advice is precious: the use and value of "second opinion" given by an interdisciplinary cancer center: *Dtsch Med Wochenschr* 2007; 132: 921-26
30. Wieder H, Rosenberg R, **Lordick F**, Geinitz H, Beer A, Becker K, Woertler K, Dobritz M, Siewert JR, Rummeny EJ, Stollfuss JC. Rectal Cancer: MR imaging before neoadjuvant chemotherapy and radiation therapy for prediction of tumor-free resections margins and long-term survival. *Radiology* 2007; 243: 744-51
31. Langer R, Specht K, Becker K, Ewald P, Ott K, **Lordick F**, Siewert JR, Hofler H. Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-Fluorouracil- and Cisplatin-based neoadjuvant chemotherapy. *Am J Clin Pathol*. 2007 128: 191-197
32. **Lordick F**, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Hoefler H, Fink U, Peschel C, Schwaiger M, Siewert JR. Use of PET to assess early metabolic response and guide treatment of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction:

a feasibility study. *Lancet Oncology* 2007; 8: 797-805

33. Napieralski R, Ott K, Kremer M, Becker K, Boulesteix AL, **Lordick F**, Siewert JR, Höfler H, Keller G. Methylation of tumor related genes in neoadjuvant treated gastric cancer: relation to therapy response, clinicopathological and molecular features. *Clin Canc Res* 2007; 13: 5095-5102
34. Siewert JR, **Lordick F**, Ott K, Stein HJ, Weber WA, Becker K, Peschel C, Fink U, Schwaiger M. Induction chemotherapy in Barrett Cancer. Influence on Surgical Risk and Outcome. *Ann Surg* 2007; 246: 624-631
35. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C, **Lordick F**. Split-dose docetaxel, cisplatin, and leucovorin/5-fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: Results of a phase II trial. *Ann Oncol* 2007; 18: 1673-1679
36. Wieder HA, Ott K, **Lordick F**, Becker K, Stahl A, Herrmann K, Fink U, Siewert JR, Schwaiger M, Weber WA. Prediction of Tumor Response by FDG-PET: Comparison of the Accuracy of Single and Sequential Studies in Patients with Adenocarcinomas of the Esophagogastric Junction. *Eur J Nucl Med* 2007; 34: 1925-1932
37. Herrmann K, Ott K, Buck AK, **Lordick F**, Wilhelm D, Souvatzoglu M, Becker K, Schuster T, Wester HJ, Siewert JR, Schwaiger M, Krause BJ. Imaging gastric cancer with positron emission tomography (PET) and the radiotracers 3'-deoxy-3'-[¹⁸F]fluorothymidine (FLT) and FDG – a comparative analysis. *J Nucl Med* 2007; 48: 1945-1950
38. Lorenzen S, Herrmann K, Weber WA, Wieder H, Hennig M, Ott K, Bredenkamp R, Peschel C, Schwaiger M, **Lordick F**. Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using (18)FDG PET. *Nuklearmedizin* 2007; 46: 263-270.
39. Gündel H, Hümmeler V, **Lordick F**. Which tumor patients profit from interdisciplinary psychoeducation in the framework of a tumor therapy? *Z Psychosom Med Psychother* 2007; 53: 324-38.
40. Rosenberg R, Nekarda H, Zimmermann F, Becker K, **Lordick F**, Hofler H, Molls M, Siewert JR. Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival. *J Surg Oncol* 2008; 97: 8-13
41. Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, Peschel C, **Lordick F**, Schwaiger M. Comparison of Integrin $\alpha\beta_3$ Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG. *J Nucl Med* 2008; 49: 22-29
42. Rodel C, Arnold D, Hipp M, Liersch T, Dellas K, Iesalnieks I, Hermann RM, **Lordick F**, Hinke A, Hohenberger W, Sauer R. Phase I-II Trial of Cetuximab, Capecitabine, Oxaliplatin, and Radiotherapy as Preoperative Treatment in Rectal Cancer. *Int J Radiat Oncol Biol Phys* 2008; 70: 1081-1087
43. Boeck S, Hoehler T, Seipelt G, Mahlberg R, Wein A, Hochhaus A, Boeck HP, Schmid B, Kettner E, Stauch M, **Lordick F**, Ko Y, Geissler M, Schoppmeyer K, Kojouharoff G, Golf A, Neugebauer S, Heinemann V. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin

(GemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. *Ann Oncol* 2008; 19: 340-47.

44. Abbrederis K, Lorenzen S, Fischer von Weikersthal L, Vehling-Kaiser U, Schuster T, Roethling N, Peschel C, **Lordick F**. Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. Results of a phase II study in pretreated patients or patients with impaired performance status. *Crit Rev Oncol Hematol* 2008; 66: 84-90.
45. Ott K, Herrmann K, **Lordick F**, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ. Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study. *Clin Cancer Res.* 2008;14:2012-2018.
46. Ott K, **Lordick F**, Becker K, Ulm K, Siewert J, Höfler H, Keller G. Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. *Int J Colorectal Dis.* 2008; 23: 773-782.
47. Bader F, **Lordick F**, Fink U, Becker K, Höfler H, Busch U, Siewert JR, Ott K. Paclitaxel in the neoadjuvant treatment for adenocarcinomas of the distal esophagus (AEG I). A comparison of two phase II trials with long term follow-up. *Onkologie* 2008; 31:366-372.
48. Arnold D, Höhler T, Dittrich C, **Lordick F**, Seufferlein T, Riemann J, Wöll E, Herrmann T, Zube A, Schmoll HJ. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin(FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. *Ann Oncol.* 2008; 19: 1142-1149
49. Lorenzen S, Brücher B, Zimmermann F, Geinitz H, Riera J, Schuster T, Roethling N, Höfler H, Ott K, Peschel C, Siewert JR, Molls M, **Lordick F**. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. *Br J Cancer.* 2008; 99: 1020-1026.
50. Schauer M, Stein H, **Lordick F**, Feith M, Theisen J, Siewert JR. Results of a Multimodal Therapy in Patients with Stage IV Barrett's Adenocarcinoma. *World J Surg.* 2008; 32: 2655-2660.
51. Langer R, Ott K, Specht K, Becker K, **Lordick F**, Burian M, Herrmann K, Schratzenholz A, Cahill MA, Schwaiger M, Höfler H, Wester HJ. Protein expression profiling in esophageal adenocarcinoma patients reveals association of heat shock protein 27 expression and chemotherapy response. *Clin Cancer Res* 2008, 14; 8279-8287.
52. Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, Kiechle M, **Lordick F**, Meindl A. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. *PLoS Medicine.* 2008;3(12):e4003.
53. Rosenberg R, Herrmann K, Gertler R, Künzli B, Essler M, **Lordick F**, Becker K, Schuster T, Geinitz H, Maak M, Schwaiger M, Siewert JR, Krause B. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced

rectal cancer measured by PET/CT. *Int J Colorectal Dis.* 2009; 24: 191-200.

54. Abbrederis K, Lorenzen S, Rothling N, Ihbe-Heffinger A, Schuster T, Peschel C, **Lordick F**. Chemotherapy-Induced Nausea and Vomiting in the Treatment of Gastrointestinal Tumors and Secondary Prophylaxis with Aprepitant. *Onkologie.* 2009; 32: 30-34.
55. Ott K, **Lordick F**, Molls M, Bartels H, Biemer E, Siewert JR. Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus. *Br J Surg.* 2009 Feb 17; 96: 258-266.
56. Ott K, Bader FG, **Lordick F**, Feith M, Bartels H, Siewert JR. Surgical Factors Influence the Outcome After Ivor-Lewis Esophagectomy with Intrathoracic Anastomosis for Adenocarcinoma of the Esophagogastric Junction: A Consecutive Series of 240 Patients at an Experienced Center. *Ann Surg Oncol.* 2009; 16: 1017-1025.
57. Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, Moehler M, Grabowski P, Arnold D, Greten T, Müller L, Röthling N, Peschel C, Langer R, **Lordick F**. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2009; 20:1667-73.
58. Stocker G, Ott K, Henningsen N, Becker K, Hapfelmeier A, **Lordick F**, Hois S, Plaschke S, Höfler H, Keller G. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. *Eur J Cancer* 2009;45:3326-35.
59. Langer R, Ott K, Feith M, **Lordick F**, Siewert JR, Becker K. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. *Mod Pathol.* 2009 Dec;22(12):1555-63.
60. Friederichs J, von Weyhern CW, Rosenberg R, Doll D, Busch R, **Lordick F**, Siewert JR, Sarbia M. Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas. *Langenbecks Arch Surg.* 2010;395(4):373-379
61. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, **Lordick F**, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. *Lancet Oncol.* 2010; 11(1):38-47.
62. **Lordick F**, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Röthling N, Schuster T, Keller G, Fend F, Peschel C. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Br J Cancer* 2010; 102(3):500-5.
63. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, **Lordick F**, Bach F, Reuter D, Edler L, Mross K. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. *Int J Clin Pharmacol Ther.* 2010 Jul;48(7):473-5

64. Langer R, Ott K, Feith M, **Lordick F**, Specht K, Becker K, Hofler H. High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. *J Surg Oncol.* 2010 Oct 1;102:503-8.
65. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, **Lordick F**, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; for the ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687-97
66. Hofheinz RD, Al-Batran SE, Ridwelski K, Görg C, Wehle K, Birth M, Fetscher S, Scheiber H, Lukan N, **Lordick F**. Population-based patterns of care in the first-line treatment of patients with advanced esophagogastric adenocarcinoma in Germany. *Onkologie.* 2010;33(10):512-8
67. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, **Lordick F**, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. *J Clin Oncol* 2010; 28(31):4706-13
68. Metz S, Ganter C, Lorenzen S, van Marwick S, Herrmann K, **Lordick F**, Nekolla SG, Rummeny EJ, Wester HJ, Brix G, Schwaiger M, Beer AJ. Phenotyping of Tumor Biology in Patients by Multimodality Multiparametric Imaging: Relationship of Microcirculation, $\alpha v \beta 3$ Expression, and Glucose Metabolism. *J Nucl Med.* 2010 Nov;51(11):1691-8.
69. Schuhmacher C, Gretschel S, **Lordick F**, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. *J Clin Oncol* 2010, 28: 5210-8
70. Lorenzen S, Panzram B, Keller G, **Lordick F**, Herrmann K, Becker K, Langer R, Schwaiger M, Siewert JR, Ott K. Association of the VEGF 936C>T Polymorphism with FDG Uptake, Clinical, Histopathological, and Metabolic Response in Patients with Adenocarcinomas of the Esophagogastric Junction. *Mol Imaging Biol* 2011 Feb;13(1):178-86
71. Ströhlein MA, Lordick F, Rüttinger D, Grützner KU, Schemanski OC, Jäger M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM. Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multicenter, Phase I/II Trial. *Onkologie.* 2011; 34(3):101-8.
72. Moehler M, Mueller A, Trarbach T, **Lordick F**, Seufferlein T, Kubicka S, Geißler M, Schwarz S, Galle PR, Kanzler S; German Arbeitsgemeinschaft Internistische Onkologie (AIO). Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. *Ann Oncol.* 2011; 22: 1358-1366

73. Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, **Lordick F**, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR; the German Arbeitsgemeinschaft Internistische Onkologie (AIO). An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. *Eur J Cancer*. 2011; 47(10):1511-1520
74. Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, **Lordick F**, Rösler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. *Bone Marrow Transplant*. 2011; 46: 2045-52
75. Ott K, Rachakonda PS, Panzram B, Keller G, **Lordick F**, Becker K, Langer R, Buechler M, Hemminki K, Kumar R. DNA Repair Gene and MTHFR Gene Polymorphisms as Prognostic Markers in Locally Advanced Adenocarcinoma of the Esophagus or Stomach Treated with Cisplatin and 5-Fluorouracil-Based Neoadjuvant Chemotherapy. *Ann Surg Oncol*. 2011; 18: 2688-98.
76. Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, **Lordick F**, Weichert W, Abel U, Debus J, Jager D, Munter MW. Sequential FDG-PET and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Oesophago gastric Junction(AEG): The Heidelberg Imaging Program in Cancer of the Oesophago-gastric junction during Neoadjuvant Treatment: HICON Trial. *BMC Cancer*. 2011 Jun 24;11(1):266
77. Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, **Lordick F**, Bach F, Reuter D, Edler L, Mross K. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. *Invest New Drugs*. 2012 Jun;30(3):1138-43
78. zum Büschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, Ott K, Ebert M, Zimmermann F, Friess H, Schwaiger M, Peschel C, **Lordick F**, Krause BJ. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. *J Nucl Med*. 2011 Aug;52(8):1189-96
79. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ, Siewert JR, Büschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Peschel C, Schwaiger M, **Lordick F**, Krause BJ. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. *Ann Surg Oncol*. 2011 Nov;18(12):3316-23
80. Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Höfler H, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, **Lordick F**. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *BMC Cancer*. 2011 Dec 7;11:509.
81. Blank S, Bläker H, Schaible A, **Lordick F**, Grenacher L, Buechler M, Ott K. Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. *Langenbecks Arch Surg*. 2012 Jan;397(1):45-55

82. Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, **Lordick F**, Jaeger D. A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-mono-clonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial. *BMC Cancer*. 2012 Mar 22;12(1):108.
83. Rahbari NN, **Lordick F**, Fink C, Bork U, Stange A, Jager D, Luntz SP, Englert S, Rossion I, Koch M, Buchler MW, Kieser M, Weitz J. Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - A randomized controlled multicentre trial (ISRCTN30964555). *BMC Cancer*. 2012 Apr 5;12(1):142.
84. Lorenzen S, Blank S, **Lordick F**, Siewert JR, Ott K. Prediction of Response and Prognosis by a Score Including Only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer Patients. *Ann Surg Oncol*. 2012; 19(7):2119-27
85. Warneke VS, Behrens HM, Haag J, Balschun K, Böger C, Becker T, Ebert MP, **Lordick F**, Röcken C. Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. *Diagn Mol Pathol*. 2013 Sep;22(3):127-37. doi: 10.1097/PDM.0b013e318284188e. PubMed PMID: 23846438.
86. **Lordick F**, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. *Lancet Oncol*. 2013 May;14(6):490-9. doi: 10.1016/S1470-2045(13)70102-5. Epub 2013 Apr 15. PubMed PMID: 23594786.
87. Lorenzen S, Thuss-Patience P, Al-Batran SE, **Lordick F**, Haller B, Schuster T, Pauligk C, Luley K, Bichev D, Schumacher G, Homann N. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. *Ann Oncol*. 2013 Aug;24(8):2068-73. doi: 10.1093/annonc/mdt141. Epub 2013 Apr 16. PubMed PMID: 23592699.
88. Blank S, **Lordick F**, Dobritz M, Grenacher L, Burian M, Langer R, Roth W, Schaible A, Becker K, Bläker H, Sisic L, Stange A, Compani P, Schulze-Bergkamen H, Jäger D, Büchler M, Siewert JR, Ott K. A reliable risk score for stage IV esophagogastric cancer. *Eur J Surg Oncol*. 2013 Aug;39(8):823-30. doi: 10.1016/j.ejso.2013.01.005. Epub 2013 Jan 31. PubMed PMID: 23375470.
89. Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jäger D, Büchler M, Siewert JR, **Lordick F**. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor. *Langenbecks Arch Surg*. 2013 Feb;398(2):239-49. doi: 10.1007/s00423-012-1039-0. Epub 2012 Dec 27. PubMed PMID: 23269519.
90. Warneke VS, Behrens HM, Böger C, Becker T, **Lordick F**, Ebert MP, Röcken C. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. *Ann Oncol*. 2013 Mar;24(3):725-33. doi: 10.1093/annonc/mds528. Epub 2012 Nov 8. PubMed PMID: 23139264; PubMed Central PMCID: PMC3574551.

91. Langer R, Becker K, Zlobec I, Gertler R, Sisic L, Büchler M, **Lordick F**, Slotta-Huspenina J, Weichert W, Höfler H, Feith M, Ott K. A Multifactorial Histopathologic Score for the Prediction of Prognosis of Resected Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy. *Ann Surg Oncol*. 2013 Nov 27. [Epub ahead of print] PubMed PMID: 24281419.
92. Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, **Lordick F**, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Cutsem EV, Buyse M, Burzykowski T; GASTRIC group. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. *J Natl Cancer Inst*. 2013 Nov 6;105(21):1600-7. doi: 10.1093/jnci/djt270. Epub 2013 Oct 9. PubMed PMID: 24108812
93. Gerlach MM, Merz F, Wichmann G, Kubick C, Wittekind C, **Lordick F**, Dietz A, Bechmann I. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. *Br J Cancer*. 2014 Jan 21;110(2):479-88. doi: 10.1038/bjc.2013.700.
94. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, **Lordick F**, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tian Y, Sidhu R. Final results from a randomized phase 3 study of FOLFIRI +/- panitumumab for second-line treatment of metastatic colorectal cancer. *Ann Oncol*. 2014 Jan;25(1):107-16
95. Blank S, Rachakonda S, Keller G, Weichert W, **Lordick F**, Langer R, Springfield C, Bruckner T, Becker K, Kumar R, Ott K. A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients. *BMC Cancer*. 2014 Feb 3;14:58
96. Langer R, Becker K, Zlobec I, Gertler R, Sisic L, Büchler M, **Lordick F**, Slotta-Huspenina J, Weichert W, Höfler H, Feith M, Ott K. A multifactorial histopathologic score for the prediction of prognosis of resected esophageal adenocarcinomas after neoadjuvant chemotherapy. *Ann Surg Oncol*. 2014 Mar;21(3):915-21
97. Homayounfar K, Bleckmann A, Helms HJ, **Lordick F**, Rüschoff J, Conradi LC, Sprenger T, Ghadimi M, Liersch T. Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases. *Br J Surg*. 2014 Apr;101(5):550-7
98. Schmidt T, Sisic L, Blank S, Becker K, Weichert W, Bruckner T, Parakonthon T, Langer R, Büchler MW, Siewert JR, **Lordick F**, Ott K. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. *Br J Cancer*. 2014 Apr 1;110(7):1712-20
99. Heger U, Blank S, Wiecha C, Langer R, Weichert W, **Lordick F**, Bruckner T, Dobritz M, Burian M, Springfield C, Grenacher L, Siewert JR, Büchler M, Ott K. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? *Ann Surg Oncol*. 2014 May;21(5):1739-48

100. Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, **Lordick F**, Hartmann JT, Stoehmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM-study). *Ann Oncol*. 2014 May;25(5):1018-25
101. Heger U, Bader F, **Lordick F**, Burian M, Langer R, Dobritz M, Blank S, Bruckner T, Becker K, Herrmann K, Siewert JR, Ott K. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. *Gastric Cancer*. 2014;17(3):478-88. doi: 10.1007/s10120-013-0296-0.
102. Fakhrian K, Ordu AD, Haller B, Theisen J, **Lordick F**, Bišof V, Molls M, Geinitz H. Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus : A comparison of two preoperative radiochemotherapy regimens. *Strahlenther Onkol*. 2014 Oct;190(11):987-992.
103. Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Santoro A, Cervantes A, Trédan O, Tournigand C, Colombo N, Dudnichenko AS, Westermann A, Friccius-Quecke H, **Lordick F**. Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. *Med Oncol*. 2014 Aug;31(8):76. doi: 10.1007/s12032-014-0076-7.
104. Karamitopoulou E, Thies S, Zlobec I, Ott K, Feith M, Slotta-Huspenina J, **Lordick F**, Becker K, Langer R. Assessment of Tumor Regression of Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy: Comparison of 2 Commonly Used Scoring Approaches. *Am J Surg Pathol*. 2014 Nov;38(11):1551-6. doi: 10.1097/PAS.0000000000000255
105. Aichler M, Motschmann M, Jütting U, Luber B, Becker K, Ott K, **Lordick F**, Langer R, Feith M, Siewert JR, Walch A. Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. *Oncotarget*. 2014 Aug 30;5(16):6620-6632
106. Fakhrian K, Ordu AD, **Lordick F**, Theisen J, Haller B, Omrčen T, Molls M, Nieder C, Geinitz H. Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU : More than 20 years' experience at a single institution. *Strahlenther Onkol*. 2014 Nov;190(12):1133-40.
107. Kuehnle MC, Attig S, Britten CM, Schulze-Bergkamen H, **Lordick F**, von Wichert G, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Türeci O. Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction. *Cancer Immunol Immunother*. 2014 Dec;63(12):1273-84
108. Singer S, Danker H, Briest S, Dietrich A, Dietz A, Eienkel J, Papsdorf K, **Lordick F**, Meixensberger J, Mössner J, Niederwieser D, Prietzel T, Schiefke F, Stolzenburg JU, Wirtz H, Kersting A. Effect of a structured psycho-oncological screening and treatment model on mental health in cancer patients (STEPPED CARE): study protocol for a cluster randomized controlled trial. *Trials* 2014 Dec 10;15:482. doi: 10.1186/1745-6215-15-482.

109. Moehler M, Baltin CT, Ebert M, Fischbach W, Gockel I, Grenacher L, Hölscher AH, **Lordick F**, Malfertheiner P, Messmann H, Meyer HJ, Palmqvist A, Röcken C, Schuhmacher C, Stahl M, Stuschke M, Vieth M, Wittekind C, Wagner D, Mönig SP. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. *Gastric Cancer*. 2015 Jul;18(3):550-63
110. Boehm A, Lindner F, Wichmann G, Bauer U, Wittekind C, Knoedler M, **Lordick F**, Dietzsch S, Scholz M, Kortmann R, Dietz A. Impact of indication-shift of primary and adjuvant chemo radiation in advanced laryngeal and hypopharyngeal squamous cell carcinoma. *Eur Arch Otorhinolaryngol*. 2015 Aug;272(8):2017-25
111. Lorenzen S, Riera Knorrenschild J, Haag GM, Pohl M, Thuss-Patience P, Bassermann F, Helbig U, Weißinger F, Schnoy E, Becker K, Stocker G, Rüschoff J, Eisenmenger A, Karapanagiotou-Schenkel I, **Lordick F**. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. *Eur J Cancer*. 2015 Mar;51(5):569-76
112. Blank S, **Lordick F**, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jäger D, Büchler M, Bruckner T, Siewert J, Ott K. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. *Gastric Cancer*. 2015 Apr;18(2):314-25
113. Fakhrian K, Ordu AD, Nieder C, **Lordick F**, Kup PG, Theisen J, Combs SE, Geinitz H. Outcomes of patients with squamous cell carcinoma of esophagus who did not receive surgical resection after neoadjuvant radiochemotherapy. *Tumori*. 2015 May-Jun;101(3):263-7. doi: 10.5301/tj.5000266.
114. Leong T, Smithers BM, Michael M, GebSKI V, Boussioutas A, Miller D, Simes J, Zalcborg J, Haustermans K, Lordick F, Schuhmacher C, Swallow C, Darling G, Wong R. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). *BMC Cancer*. 2015 Jul 21;15(1):532
115. Schmidt T, Alldinger I, Blank S, Klose J, Springfield C, Dreikhausen L, Weichert W, Grenacher L, Bruckner T, **Lordick F**, Ulrich A, Büchler MW, Ott K. Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection. *Eur J Surg Oncol*. 2015 Oct;41(10):1340-7
116. Scheffold K, Philipp R, Engelmann D, Schulz-Kindermann F, Rosenberger C, Oechsle K, Härter M, Wegscheider K, **Lordick F**, Lo C, Hales S, Rodin G, Mehnert A. Efficacy of a brief manualized intervention Managing Cancer and Living Meaningfully (CALM) adapted to German cancer care settings: study protocol for a randomized controlled trial. *BMC Cancer*. 2015 Aug 19;15(1):592
117. Peeters M, Oliner K, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, **Lordick F**, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, He P, Yu H, Koukakis R, Terwey JH, Jung AS, Sidhu R, Patterson SD. Analysis of KRAS/NRAS Mutations in a Phase 3 Study of Panitumumab With FOLFIRI Compared With FOLFIRI Alone as Second-Line Treatment for Metastatic

118. Springfield C, Wiecha C, Kunzmann R, Heger U, Weichert W, Langer R, Stange A, Blank S, Sasic L, Schmidt T, **Lordick F**, Jäger D, Grenacher L, Bruckner T, Büchler MW, Ott K. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. *Ann Surg Oncol*. 2015 Dec;22 Suppl 3:905-14
119. Dietz A, Loeffler M, Rosolowski M, Kreuz M, **Lordick F**, Knödler M, Mozet C, Wichmann G. [Gene expression analyses and their possible clinical benefit in head and neck cancer]. *HNO*. 2015 Nov;63(11):773-85. doi: 10.1007/s00106-015-0078-6.
120. Koerfer J, Kallendrusch S, Merz F, Wittekind C, Kubick C, Kassahun WT, Schumacher G, Moebius C, Gaßler N, Schopow N, Geister D, Wiechmann V, Weimann A, Eckmann C, Aigner A, Bechmann I, **Lordick F**. Organotypic slice cultures of human gastric and esophagogastric junction cancer. *Cancer Med*. 2016 Jul;5(7):1444-53
121. Janmaat VT, Bruno MJ, Polinder S, Lorenzen S, **Lordick F**, Peppelenbosch MP, Spaander MC. Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma. *PLoS One*. 2016 Apr 21;11(4):e0153943. doi: 10.1371/journal.pone.0153943. eCollection 2016. PubMed PMID: 27100871
122. Alt-Epping B, Seidel W, Vogt J, Mehnert A, Thomas M, van Oorschot B, Wolff H, Schliephake H, Canis M, Dröge LH, Nauck F, **Lordick F**; Arbeitsgemeinschaft Palliativmedizin (APM) of the German Cancer Society (DKG). Symptoms and Needs of Head and Neck Cancer Patients at Diagnosis of Incurability - Prevalences, Clinical Implications, and Feasibility of a Prospective Longitudinal Multicenter Cohort Study. *Oncol Res Treat* 2016; 39(4): 186-91
123. Hoepfner J, **Lordick F**, Brunner T, Glatz T, Bronsert P, Röthling N, Schmoor C, Lorenz D, Ell C, Hopt UT, Siewert JR. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). *BMC Cancer*. 2016 Jul 19;16(1):503
124. Engelmann D, Scheffold K, Friedrich M, Hartung TJ, Schulz-Kindermann F, **Lordick F**, Schilling G, Lo C, Rodin G, Mehnert A. Death-related anxiety in patients with advanced cancer: Validation of the German version of the Death and Dying Distress Scale (DADDS-G). *J Pain Symptom Manage*. 2016 Oct;52(4):582-587
125. Shah MA, Bang YJ, **Lordick F**, Alsina M, Chen M, Hack SP, Bruey JM, Smith D, McCaffery I, Shames DS, Phan S, Cunningham D. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. *JAMA Oncol*. 2017 May 1;3(5):620-627
126. Pfirrmann D, Tug S, Brosteanu O, Mehdorn M, Busse M, Grimminger PP, Lordick F, Glatz T, Hoepfner J, Lang H, Simon P, Gockel I. Internet-based perioperative exercise program in patients with Barrett's carcinoma scheduled for esophagectomy [iPEP - study] a prospective randomized-controlled trial. *BMC Cancer*. 2017 Jun 14;17(1):413.
127. Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, Tufano A, **Lordick F**, De Simone B, Muehlberg KS, Bruzzese D, Attademo L, Arturo C, Sodano M, Moretto R, La Fata E, De Placido S. Preventing Venous

Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV study. *Oncologist*. 2017 May;22(5):601-608.

128. Leong T, Smithers BM, Haustermans K, Michael M, GebSKI V, Miller D, ZalcbErg J, Boussioutas A, Findlay M, O'Connell RL, Verghis J, Willis D, Kron T, Crain M, Murray WK, **Lordick F**, Swallow C, Darling G, Simes J, Wong R. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. *Ann Surg Oncol*. 2017 Aug;24(8):2252-2258
129. Haag GM, Stocker G, Quidde J, Jaeger D, **Lordick F**. Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer – the multinational MATEO study. *BMC Cancer*. 2017 Jul 31;17(1):509. doi:10.1186/s12885-017-3497-9
130. Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Hänel M, Salwender HJ, Weisel K, Dürig J, Görner M, Kirchner H, Peter N, Graeven U, **Lordick F**, Hoffmann M, Reimer P, Blau IW, Jauch A, Dembowski K, Möhler T, Wuchter P, Goldschmidt H. Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. *Bone Marrow Transplant*. 2017 Aug;52(8):1194-1198
131. Kataoka K, Kinoshita T, Moehler M, Mauer M, Shitara K, Wagner AD, Schrauwen S, Yoshikawa T, Roviello F, Tokunaga M, Boku N, Ducreux M, Terashima M, **Lordick F**. Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. *Gastric Cancer*. 2017 Sep;20(5):904-912
132. Kunzke T, Balluff B, Feuchtinger A, Buck A, Langer R, Luber B, **Lordick F**, Zitzelsberger H, Aichler M, Walch A. Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome. *Oncotarget*. 2017 Jul 10;8(40):68012-68025.
133. Spoerl S, Novotny A, Al-Batran SE, Lordick F, Thuss-Patience P, Pauligk C, Haller B, Feith M, Lorenzen S. Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. *Eur J Cancer*. 2017 Dec 19; 90: 26-33
134. Sönnichsen R, Hennig L, Blaschke V, Winter K, Körfer J, Hänel S, Monecke A, Wittekind C, Jansen-Winkel B, Thieme R, Gockel I, Grosser K, Weimann A, Kubick, C, Wiechmann V, Aigner A, Bechmann I, **Lordick F**, Kallendrusch S. Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma. *Clin Colorectal Cancer*. 2018 Jun;17(2):e189-e199
135. Urban C, Buck A, Siveke JT, **Lordick F**, Luber B, Walch A, Aichler M. PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSI. *Biochim Biophys Acta*. 2018 Jan;1862(1): 51-60
136. Roick J, Danker H, Kersting A, Briest S, Dietrich A, Dietz A, Einkenkel J, Papsdorf K, **Lordick F**, Meixensberger J, Mössner J, Niederwieser D, Prietzel T, Schiefke F, Stolzenburg JU, Wirtz H, Singer S. Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial. *Eur J Cancer Care (Engl)*. 2018 Jan; 27(1). doi:10.1111/ecc.12645.
137. Stahl M, Maderer A, **Lordick F**, Mihaljevic AL, Kanzler S, Hoehler T, Thuss-Patience P, Mönig S, Kunzmann V, Schroll S, Sandermann A, Tannapfel A, Meyer

- HJ, Schuhmacher C, Wilke H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie (AIO) Oesophageal and Gastric Cancer Working Group and the Chirurgische Arbeitsgemeinschaft Onkologie (CAOGI/DGAV) of the German Cancer Society. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). *Eur J Cancer*. 2018 Mar 1; 93: 119-126.
138. Lelorain S, Cattan S, **Lordick F**, Mehnert A, Mariette C, Christophe V, Cortot A. In which context is physician empathy associated with cancer patient quality of life? *Patient Educ Couns*. 2018 Jul;101(7):1216-1222. doi: 10.1016/j.pec.2018.01.023
139. Spoerl S, Novotny A, Al-Batran SE, **Lordick F**, Thuss-Patience P, Pauligk C, Haller B, Feith M, Lorenzen S. Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. *Eur J Cancer*. 2018 Feb; 90: 26-33.
140. Polom K, Böger C, Smyth E, Marrelli D, Behrens HM, Marano L, Becker T, **Lordick F**, Röcken C, Roviello F. Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. *Eur J Surg Oncol*. 2018 May;44(5):626-631
141. Stocker G, Hacker UT, Fiteni F, John Mahachie J, Roth AD, Van Cutsem E, Peeters M, **Lordick F**, Mauer M. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study. *Eur J Cancer*. 2018 Jun 12; 99: 49-57
142. Berger AK, Lücke S, Abel U, Haag GM, Grüllich C, Stange A, Dietrich M, Apostolidis L, Freitag A, Trierweiler C, von Gall C, Ose J, Giesel F, Weber TF, **Lordick F**, Haberkorn U, Jäger D. Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial. *Br J Cancer*. 2018 Jul;119(2):170-175
143. Esser P, Kuba K, Mehnert A, Johansen C, Hinz A, **Lordick F**, Götze H. Quality of life in survivors of hematological malignancies stratified by cancer type, time since diagnosis and stem cell transplantation. *Eur J Haematol*. 2018 Sep;101(3):340-348
144. Knödler M, Körfer J, Kunzmann V, Trojan J, Daum S, Schenk M, Kullmann F, Schroll S, Behringer D, Stahl M, Al-Batran SE, Hacker U, Ibach S, Lindhofer H, **Lordick F**. Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. *Br J Cancer*. 2018 Aug;119(3):296-302
145. Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, **Lordick F**, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J; AME Thoracic Surgery Collaborative Group. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. *J Clin Oncol*. 2018 Sep 20;36(27):2796-2803

146. Götze H, Taubenheim S, Dietz A, **Lordick F**, Mehnert A. Comorbid conditions and health-related quality of life in long-term cancer survivors-associations with demographic and medical characteristics. *J Cancer Surviv.* 2018 Oct;12(5):712-720
147. Heinrichs SKM, Hess T, Becker J, Hamann L, Vashist YK, Butterbach K, Schmidt T, Alakus H, Krasniuk I, Höblinger A, Lingohr P, Ludwig M, Hagel AF, Schildberg CW, Veits L, Gyvyte U, Weise K, Schüller V, Böhmer AC, Schröder J, Gehlen J, Kreuser N, Hofer S, Lang H, **Lordick F**, Malfertheiner P, Moehler M, Pech O, Vassos N, Rodermann E, Izbicki JR, Kruschewski M, Ott K, Schumann RR, Vieth M, Mangold E, Gasenko E, Kupcinkas L, Brenner H, Grimminger P, Bujanda L, Sopeña F, Espinel J, Thomson C, Pérez-Aísa Á, Campo R, Geijo F, Collette D, Bruns C, Messerle K, Gockel I, Nöthen MM, Lippert H, Ridwelski K, Lanás A, Keller G, Knapp M, Leja M, Kupcinkas J, García-González MA, Venerito M, Schumacher J. Evidence for PTGER4, PSCA, and MBOAT7 as risk genes for gastric cancer on the genome and transcriptome level. *Cancer Med.* 2018 Oct;7(10):5057-5065
148. Dietz A, Wichmann G, Kuhnt T, Pfreundner L, Hagen R, Scheich M, Kölbl O, Hautmann MG, Strutz J, Schreiber F, Bockmühl U, Schilling V, Feyer P, de Wit M, Maschmeyer G, Jungehülsing M, Schroeder U, Wollenberg B, Sittel C, Münter M, Lenarz T, Klusmann JP, Guntinas-Lichius O, Rudack C, Eich HT, Foerg T, Preyer S, Westhofen M, Welkoborsky HJ, Esser D, Thurnher D, Remmert S, Sudhoff H, Görner M, Bünzel J, Budach V, Held S, Knödler M, **Lordick F**, Wiegand S, Vogel K, Boehm A, Flentje M, Keilholz U. Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. *Ann Oncol.* 2018 Oct 1;29(10):2105-2114
149. Gockel I, Jansen-Winkel B, Haase L, Rhode P, Mehdorn M, Niebisch S, Moulla Y, Lyros O, **Lordick F**, Schierle K, Wittekind C, Thieme R. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study. *J Gastric Cancer.* 2018 Dec;18(4):379-391
150. Zeynalova N, Schimpf S, Setter C, Yahiaoui-Doktor M, Zeynalova S, **Lordick F**, Loeffler M, Hinz A. The association between an anxiety disorder and cancer in medical history. *J Affect Disord.* 2019 Mar 1;246:640-642
151. Jansen-Winkel B, Thieme R, Haase L, Niebisch S, Pommer C, Lyros O, Zimmer J, **Lordick F**, Remane Y, Frontini R, Gockel I. [Perioperative safety of intraperitoneal aerosol chemotherapy : Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures]. *Chirurg.* 2019 Feb;90(2):137-145
152. van den Boorn HG, Abu-Hanna A, Ter Veer E, van Kleef JJ, **Lordick F**, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM. SOURCE: Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. *Cancers (Basel).* 2019 Feb 5;11(2). pii: E187. doi: 10.3390/cancers11020187. PubMed PMID: 30764578.
153. Kuba K, Esser P, Mehnert A, Hinz A, Johansen C, **Lordick F**, Götze H. Risk for depression and anxiety in long-term survivors of hematologic cancer. *Health Psychol.* 2019 Mar; 38(3): 187-195
154. Götze H, Köhler N, Taubenheim S, **Lordick F**, Mehnert A. Polypharmacy, limited activity, fatigue and insomnia are the most frequent symptoms and impairments in

older hematological cancer survivors (70+): Findings from a register-based study on physical and mental health. *J Geriatr Oncol.* 2019 Jan;10(1):55-59

155. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, **Lordick F**, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bhagia P, Kato K. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. *JAMA Oncol.* 2018 Dec 20. doi: 10.1001/jamaoncol.2018.5441. [Epub ahead of print]

156. Götze H, Friedrich M, Taubenheim S, Dietz A, **Lordick F**, Mehnert A. Depression and anxiety in long-term survivors 5 and 10 years after cancer diagnosis. *Support Care Cancer.* 2019 Apr 18. doi: 10.1007/s00520-019-04805-1. [epub]

157. Kotzerke D, Moritz F, Mantovani L, Hamsch P, Hering K, Kuhnt T, Yahiaoui-Doktor M, Forstmeyer D, **Lordick F**, Knödler M. The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study. *J Geriatr Oncol.* 2019 May 10. pii: S1879-4068(18)30525-3. doi:10.1016/j.jgo.2019.04.004. [Epub ahead of print]

Reviews and Editorials in peer-reviewed journals

1. Weber WA, Ott K, **Lordick F**. PET bei Ösophagus- und Magenkarzinom. *Der Nuklearmediziner* 2003; 26: 104-109
2. **Lordick F**, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy in oesophago-gastric cancer. *Br J Surg* 2004; 91: 540-551
3. Stein HJ, **Lordick F**, Siewert JR. Ösophaguskarzinom. Chirurgische und multimodale Therapie. *Chirurgische Gastroenterologie* 2004; 20:13-20
4. Stahl A, Wieder H, Wester HJ, Piert M, **Lordick F**, Ott K, Rummeny E, Schwaiger M, Weber WA. PET/CT Molecular Imaging for Abdominal Oncology. *Abdom Imaging* 2004; 29: 388-397
5. **Lordick F**, Rosenberg R, Stein HJ, Peschel C, Siewert JR. Adjuvant therapy for colon cancer. *Dtsch Med Wochenschr* 2004; 129: 2366-2371
6. Rahden BHA, **Lordick F**. Adjuvante Chemotherapie beim Plattenepithelkarzinom des Ösophagus. *Chirurg* 2004; 75: 637-638
7. Rahden BHA, **Lordick F**, Sendler A, Ulm K. Neuer Standard der adjuvanten Chemotherapie beim Pankreaskarzinom. *Chirurg* 2004; 75: 1034-1036
8. **Lordick F**, Ihbe-Heffinger A, Peschel C. Antiemetic prophylaxis in the chemotherapy of gastrointestinal tumours. *Zeitschrift für Gastroenterologie* 2005; 43: 391-398
9. **Lordick F**, Siewert JR. Multimodal treatment for gastric cancer. *Gastric Cancer* 2005; 8: 78-85
10. **Lordick F**, Siewert JR. Neoadjuvant treatment for gastric cancer. *Der Onkologe* 2005; 11: 640-649
11. **Lordick F**, Peschel C, Siewert JR. Antibody-based targeted therapy for gastric cancer: is it time to go for it? *Gastric Cancer* 2005; 8: 205-206
12. **Lordick F**. Neoadjuvant treatment for squamous cell cancer of the esophagus. *Der Chirurg* 2005; 76: 1025-1032
13. Braun-Falco M, Holtmann C, **Lordick F**, Ring J. Follicular drug reaction from cetuximab. A common side effect in the treatment of metastatic colon carcinoma. *Hautarzt* 2006; 57: 701-704
14. Siewert JR, **Lordick F**, Ott K, Brucher BL, Rosenberg R. Curative vs palliative strategies in locoregional recurrence of gastrointestinal malignancies. *Chirurg.* 2006 239; 227-235
15. Reinacher-Schick A, Arnold D, **Lordick F**, Mohler M, Lutz MP, Seufferlein T. ASCO Update 2006 - Highlights of the 42. Meeting of the American Society of Clinical Oncology/ASCO 2006. *Z Gastroenterol* 2006; 44:1065-1072
16. **Lordick F**, Siewert JR. Perioperative chemotherapy versus surgery alone in resectable gastroesophageal cancer. *Chirurg* 2006;77:1166-1167

17. Ebert M, Yu J, **Lordick F**, Röcken C. Proteomics in gastrointestinal cancer. *Ann Oncol* 2006; 17(Suppl10): 253-258
18. Siewert JR, **Lordick F**. Response prediction – early response evaluation. Consequences for surgical oncology. *Chirurg* 2006;77:1095-1103
19. Bumm R, Feith M, Lordick F, Herrschbach P, Siewert JR. Impact of multidisciplinary tumor boards on diagnosis and treatment of esophageal cancer. *Eur Surg* 2007; 39/3: 136-140
20. **Lordick F**, Ebert M, Stein HJ. Current treatment approach to locally advanced esophageal cancer: Is resection mandatory? *Future Oncology* 2006;2:717-721
21. **Lordick F**, Ott K, Novotny A, Schuhmacher C, Siewert JR. R1 resection in the surgery of upper gastrointestinal tumors. Relevance and therapeutical consequences. *Chirurg* 2007; 78: 792-801
22. Arnold D, **Lordick F**. Systemic treatment of peritoneal metastases. *Chirurg* 2007; 78: 117-1122
23. **Lordick F**, Hölscher AH. Chirurgische und Internistische Diagnostik und Therapie des Ösophaguskarzinoms. *Gastroenterologie up2date* 2007; 3: 291-319
24. Wieder H, Stahl A, **Lordick F**, Ott K. Esophageal Cancer. *Recent Results Cancer Res* 2008; 170: 71-79.
25. Van Cutsem E, Van de Velde C, Roth A, **Lordick F**, Köhne CH, Cascinu S, Apro M. Expert paper on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organization for Research and Treatment of Cancer (EORTC) - Gastrointestinal Cancer Group. *Eur J Cancer* 2008; 44: 182-194
26. Ott K, **Lordick F**, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR. The new credo. Induction chemotherapy in locally advanced gastric cancer. Consequences for surgical strategies. *Gastric Cancer* 2008;11:1-9
27. **Lordick F**, Siewert JR. Bevacizumab (Avastin®) related surgical complications. *Chirurg* 2008; 79: 356-360
28. **Lordick F**, Schulze T. Molekulare Prognosefaktoren und neue systemische Therapien beim Magenkarzinom. *Der Onkologe* 2008; ; 14: 389-395 DOI 10.1007/s00761-008-1339-8
29. **Lordick F**, Schulze T, Jäger D. The role of biologics in stomach cancer. *Target Oncol* 2008DOI 10.1007/s11523-008-0078-5.
30. Siewert JR, **Lordick F**, Ott K, Stein HJ. Adenocarcinoma of the distal esophagus (type I) and adenocarcinoma of the gastric cardia (type II): Is it one tumor entity? *Ann Surg* 2008; 247: 1081.
31. Heger U, Weitz J, **Lordick F**. Indications for pre- and postoperative treatment with imatinib for GIST. *Chirurg* 2008; 79: 630-637.
32. **Lordick F**, Ruers T, Aust DE, Collette L, Downey RJ, El Hajjam M, Flamen P, Haustermans K, Ilson D, Julié C, Krause BJ, Newiger N, Ott K, Roth A, Van Cutsem E, Weber WA, Lutz M on behalf of the EORTC Gastrointestinal Cancer Tract Working Group. European Organization of Research and Treatment of Cancer (EORTC)

Gastrointestinal Tract Cancer Working Group: workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. *Eur J Canc* 2008; 1807-1819.

33. **Lordick F**, Ott K, Weitz J, Jäger D. The evolving role for catumaxumab in gastric cancer. *Expert Opin Biol Ther* 2008; 8: 1407-1415.
34. **Lordick F**, Krauß J, Jäger D. Tumor marker and biomarker in head and neck cancer. *HNO, Springer* 2008; 56: 881-885.
35. **Lordick F**, Jäger D. The Current Status and Future of Biochemotherapy in Gastroesophageal Cancers. *Gastroint Canc Res* 2008; 2: 187-197.
36. Ott K, Herrmann K, Krause BJ, **Lordick F**. The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer. *Gastrointest Cancer Res.* 2008 Nov;2(6):287-94.
37. Hartwig W, Strobel O, **Lordick F**, Büchler MW, Werner J. Multimodal therapy of esophageal cancer. *Z Gastroenterol.* 2008 Oct;46(10):1207-13.
38. **Lordick F**, Ridwelski K, Al-Batran SE, Trarbach T, Schlag PM, Piso P. Treatment of Gastric Cancer. *Onkologie* 2008; 31(suppl5):32-39
39. **Lordick F**. Multimodal treatment for adult soft tissue sarcomas. *Chirurg* 2009 80: 209-215.
40. Cmelak AJ, **Lordick F**, Borner M, Goldberg RM, Saif MW. Management of infusion reactions in clinical trials and beyond: the US and EU perspectives. *Oncology (Williston Park).* 2009; 23(2 Suppl 1): 18-25.
41. **Lordick F**, Ott K. Neoadjuvante und adjuvante Therapie des Magen- und Ösophaguskarzinoms. *Der Gastroenterologe* 2009; 4: 224-231.
42. Ott K, **Lordick F**. Neoadjuvant therapy in the upper gastro-intestinal tract: Gastric cancer from a surgical viewpoint. *Chirurg* 2009; 80: 1029-1034.
43. **Lordick F**. Principles of neoadjuvant therapy. *Chirurg.* 2009; 80: 1000-1005.
44. Czito B, **Lordick F**. Accomplishments in 2008 in the adjuvant treatment of rectal cancer. *Gastrointest Cancer Res.* 2009 Sep;3(5 Supplement 2):S8-S14.
45. **Lordick F**, Lorenzen S. System therapy of esophageal carcinoma and the value of targeted therapies. *Onkologie* 2010; 16: 515-520.
46. **Lordick F**, Grenacher L, Röcken C, Ebert M, Moehler M, Schumacher G. Diagnosis and treatment of gastric cancer. *Dtsch Med Wochenschr.* 2010 Aug;135(34/35):1671-1682
47. **Lordick F**, Ott K, Krause BJ. New trends for staging and therapy for localized gastroesophageal cancer: the role of PET. *Ann Oncol.* 2010 Oct;21 Suppl7:vii294-vii299.
48. Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, **Lordick F**, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, Trarbach T, Wollenberg A. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.

49. **Lordick F.** Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. *Future Oncol.* 2011 Feb;7(2):187-99.
50. Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J, Feußner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler M, Gockel I, Graeven U, Grenacher L, Groß S, Hartmann JT, Heike M, Heinemann V, Herbst B, Herrmann T, Höcht S, Hofheinz RD, Höfler H, Höhler T, Hölscher AH, Horneber M, Hübner J, Izbicki JR, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Körber J, Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, **Lordick F**, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Mönig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag PM, Schmid RM, Schmidberger H, Schmiegel WH, Schmoll HJ, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Tremel K, Vanhoefer U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C. [German S3-Guideline "Diagnosis and Treatment of Esophagogastric Cancer"]. *Z Gastroenterol.* 2011 Apr;49(4):461-531
51. **Lordick F**, Ott K, Krause BJ. Positron emission tomography - current role in the diagnosis and treatment of upper gastrointestinal carcinomas. *Dtsch Med Wochenschr.* 2011 May;136(20):1061-1066
52. Lorenzen S, **Lordick F.** How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer? *Curr Opin Oncol.* 2011; 23: 396-402
53. Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, **Lordick F**, Ohtsu A, Pavlidis N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C, Zalcberg J. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. *Ann Oncol.* 2011 Jun;22 Suppl 5:v1-9
54. Ott K, **Lordick F**, Blank S, Büchler M. Gastric cancer: surgery in 2011. *Langenbecks Arch Surg.* 2011; 6: 743-758
55. **Lordick F.** Current standard and trends in oesophageal cancer. *Eur J Cancer.* 2011 Sep;47 Suppl 3:S353-4
56. **Lordick F**, Ott K, Sendler A. [Gastric cancer and adenocarcinoma of the esophagogastric junction : Principles of neoadjuvant therapy.]. *Chirurg* 2011 Nov;82(11):968-73.
57. **Lordick F.** HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges. *Clin Transl Oncol.* 2011 Sep;13(9):597-8
58. **Lordick F.** The role of PET in predicting response to chemotherapy in oesophago-gastric cancer. *Acta Gastroenterol Belg.* 2011 Dec;74(4):530-5.
59. Meyer HJ, Hölscher AH, **Lordick F**, Messmann H, Mönig S, Schumacher C, Stahl M, Wilke H, Möhler M. [Current S3 guidelines on surgical treatment of gastric

carcinoma.]. Chirurg. 2012 Jan;83(1):31-7.

60. **Lordick F.** Supportive treatment – an integral part of cancer care. Magazine of European Medical Oncology 2012; 5: 1-2
61. **Lordick F.** Gastrointestinal cancer: Salvage chemotherapy in gastric cancer--more than a straw? Nat Rev Clin Oncol. 2012 May 1;9(6):312-3.
62. **Lordick F.** To Resect or not resect in metastatic gastric cancer: that is the question. Gastric Cancer 2012 Jul;15(3):229-31.
63. **Lordick F.** [Value of postoperative radiochemotherapy after completely resected gastric cancer not definitive despite negative overall results of the ARTIST trial]. Strahlenther Onkol. 2012 Jul;188(7):636-7
64. Grenacher L, Schwarz M, **Lordick F**, Krause B, Roecken C, Moenig S, Ebert M, Jenssen C, Kauczor HU, Moehler M. [S3 Guideline - Diagnosis and Treatment of Gastric Carcinoma: Relevance for Radiologic Imaging.]. Rofo. 2012 Aug;184(8):706-12.
65. **Lordick F**, van Oorschot B. Palliative medicine in oncology. Objectives of the working group on palliative medicine of the German Cancer Society. Forum 2012; DOI: 10.1007/s12312-012-0838-0 (online first)
66. Lutz MP, Zalcborg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J, Jansen EP, Kisslich R, **Lordick F**, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012 Nov;48(16):2941-53
67. **Lordick F.** Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography. Recent Results Cancer Res 2012;196:201-11
68. **Lordick F**, Hölscher AH, Haustermans K, Wittekind C. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg. 2013 Feb;398(2):177-87. doi: 10.1007/s00423-012-1001-1. Epub 2012 Sep 13. Review. PubMed PMID: 22971784.
69. Lorenzen S, **Lordick F.** Therapie des fortgeschrittenen Magenkarzinoms. Onkologie 2013; 84:389–394.
70. **Lordick F.** [Comments on the statement of the German Society of Pathology (DGP) on clinical studies from a clinical perspective]. Pathologe. 2013 Sep;34(5):476-8. doi: 10.1007/s00292-013-1797-7. German. PubMed PMID: 23881238.
71. Wilke H, **Lordick F**, Meyer HJ, Stahl M. (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the west. Dig Surg. 2013;30(2):112-8. doi: 10.1159/000350935. Epub 2013 Jul 18. PubMed PMID: 23867587.
72. **Lordick F**, Röcken C. The identification of predictive factors for perioperative chemotherapy in esophago-gastric cancer. Ann Oncol. 2013 May;24(5):1135-8. doi: 10.1093/annonc/mdt111. Epub 2013 Mar 19. PubMed PMID:

73. **Lordick F**, Jähne J. Evidence-Based Medicine oder Erfahrungsmedizin - Grenzenscheidungen in der Onkologie benötigen den erfahrenen Arzt. *Viszeralmedizin* 2013; 29:205–206
74. **Lordick F**, Forstmeyer D, Ahlborn M, Becker-Schiebe M, Hoffmann W, Schumacher G. Medical Treatment of Peritoneal Carcinomatosis. *Viszeralmedizin* 2013; 29:213–219
75. Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, Dux M, Farkas S, Folprecht G, Galle P, Geißler M, Gerken G, Habermehl D, Helmberger T, Herfarth K, Hoffmann RT, Holtmann M, Huppert P, Jakobs T, Keller M, Klempnauer J, Kolligs F, Körber J, Lang H, Lehner F, **Lordick F**, Lubienski A, Manns MP, Mahnken A, Möhler M, Mönch C, Neuhaus P, Niederau C, Ocker M, Otto G, Pereira P, Pott G, Riemer J, Ringe K, Ritterbusch U, Rummeny E, Schirmacher P, Schlitt HJ, Schlottmann K, Schmitz V, Schuler A, Schulze-Bergkamen H, von Schweinitz D, Seehofer D, Sitter H, Straßburg CP, Stroszczyński C, Strobel D, Tannapfel A, Trojan J, van Thiel I, Vogel A, Wacker F, Wedemeyer H, Wege H, Weinmann A, Wittekind C, Wörmann B, Zech CJ. [Diagnosis of and therapy for hepatocellular carcinoma]. *Z Gastroenterol.* 2013 Nov;51(11):1269-326. doi: 10.1055/s-0033-1355841. Epub 2013 Nov 15. German. PubMed PMID: 24243572.
76. Oorschot BV, Rades D, **Lordick F**. Connections are clearly more complex. *Dtsch Arztebl Int.* 2013 Nov 1;110(44):753. doi: 10.3238/arztebl.2013.0753a. PubMed PMID: 24280433; PubMed Central PMCID: PMC3831243.
77. **Lordick F**, Knödler M, Hacker U, Bartels M. [Neoadjuvant chemotherapy or primary surgery for colorectal liver metastases. Pro adjuvant chemotherapy]. *Chirurg.* 2014 Jan;85(1):11-6
78. Dietz A, Knödler M, **Lordick F**. Primary treatment of head and neck tumors. *Der Onkologe* 2014; 20:144-151
79. **Lordick F**, Hoffmeister A. [Treatment of gastric cancer]. *Internist (Berl).* 2014 Jan;55(1):15-22
80. **Lordick F**, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? *Gastric Cancer.* 2014 Apr;17(2):213-25
81. Ahlborn M, **Lordick F**. Fortgeschrittenes Pankreaskarzinom. Möglicher Einfluss der Mistel auf das Überleben. *Der Onkologe* 2014; 20: 376-378
82. **Lordick F**, Allum W, Carneiro F, Mityr E, Tabernero J, Tan P, Van Cutsem E, van de Velde C, Cervantes A. Unmet needs and challenges in gastric cancer: The way forward. *Cancer Treat Rev.* 2014 Jul;40(6):692-700
83. Brücher BL, Lyman G, van Hillegersberg R, Pollock RE, **Lordick F**, Yang HK, Ushijima T, Yeoh KG, Skricka T, Polkowski W, Wallner G, Verwaal V, Garofalo A, D'Ugo D, Roviello F, Steinau HU, Wallace TJ, Daumer M, Maihle N, Reid TJ 3rd, Ducreux M, Kitagawa Y, Knuth A, Zilberstein B, Steele SR, Jamall IS. Imagine a world without cancer. *BMC Cancer.* 2014 Mar 14;14:186. doi: 10.1186/1471-2407-14-186

84. Homayounfar K, **Lordick F**, Ghadimi M. Qualitätssicherung: Multidisziplinäre Tumorboards – trotz Problemen unverzichtbar. Dtsch Arztebl 2014; 111(22): A-998 / B-852 / C-806
85. Ott K, Schmidt T, **Lordick F**, Herrmann K. Importance of PET in surgery of esophageal cancer. Chirurg. 2014 Jun;85(6):505-12. doi: 10.1007/s00104-013-2668-8.
86. Gomez-Martín C, Lopez-Rios F, Aparicio J, Barriuso J, García-Carbonero R, Pazo R, Rivera F, Salgado M, Salud A, Vázquez-Sequeiros E, **Lordick F**. A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond. Cancer Lett. 2014 Aug 28;351(1):30-40. doi: 10.1016/j.canlet.2014.05.019.
87. **Lordick F**. Targeting the HGF/MET pathway in gastric cancer. Lancet Oncol. 2014 Aug;15(9):914-6. doi: 10.1016/S1470-2045(14)70273-6
88. **Lordick F**, Ricke J, Mohnike K, Hacker U. How to Create Evidence for the Integration of Local and Locoregional Treatments in Future Oncological Treatment Concepts? Viszeralmedizin 2014;30:261-268
89. Lorenzen S, Spörl S, **Lordick F**. [Incidence and Treatment of Chemotherapy-Induced Nausea and Emesis in Gastrointestinal Cancer.]. Z Gastroenterol. 2014 Aug;52(8):821-830. Epub 2014 Aug 11. German. PubMed PMID: 25111723.
90. **Lordick F**. Rectal Cancer with Synchronous Liver Metastases: Leave It All in? When (not) to Resect the Primary? Recent Results Cancer Res. 2014;203:231-41. doi: 10.1007/978-3-319-08060-4_16. PubMed PMID: 25103009.
91. **Lordick F**. Mistletoe treatment for cancer-promising or passé? Dtsch Arztebl Int. 2014 Jul 21;111(29-30):491-2
92. Aichler M, Lubber B, **Lordick F**, Walch A. Proteomic and metabolic prediction of response to therapy in gastric cancer. World J Gastroenterol. 2014 Oct 14;20(38):13648-13657
93. **Lordick F**. Algorithmus zur stadiengerechten Primärbehandlung von Patienten mit Ösophaguskarzinom. Der Onkologe 2014; 20:1179–1179
94. **Lordick F**, Hölscher A, Höchst S, Bamberg M. Ösophaguskarzinom – Interdisziplinarität und Qualität gefragt. Der Onkologe 2014; 20:1177–1178
95. **Lordick F**. Gastrointestinal cancer: Over the RAINBOW-renaissance in antiangiogenesis. Nat Rev Clin Oncol. 2015 Jan;12(1):7-8
96. Schmidt T, **Lordick F**, Herrmann K, Ott K. Value of Functional Imaging by PET in Esophageal Cancer. J Natl Compr Canc Netw. 2015 Feb;13(2):239-247
97. **Lordick F**, Gockel I, Wittekind C. Magenkarzinom: Neue molekulare Konzepte. Dtsch Arztebl 2015; 112(20): [4]; DOI: 10.3238/PersOnko.2015.05.15.01
98. **Lordick F**. Neuer Angiogenesehemmer Ramucirumab: Längeres Überleben und bessere Symptomkontrolle. Oncol Res Treat. 2015;38(5):260-3

99. Hacker U, **Lordick F**. [Current standards in the treatment of gastric cancer]. Dtsch Med Wochenschr. 2015 Aug;140(16):1202-5
100. Behrens A, Ell C, **Lordick F**. Perioperative and Palliative Chemotherapy for Esophageal Cancer. Viszeralmedizin 2015;31:341–346
101. Gockel I, Hoffmeister A, **Lordick F**. [Neoadjuvant therapy for tumors of the upper gastrointestinal tract: Complication management]. Chirurg 2015. Nov;86(11):1014-22
102. Dietz A, **Lordick F**. Update Skills in Head and Neck Surgery and Oncology 2015. Aktuelles klinikrelevantes Wissen praxisnah präsentiert. HNO. 2015 63(12):880-1
103. **Lordick F**, Hacker U. [Weight loss in cancer patients]. Dtsch Med Wochenschr. 2016 Feb;141(4):247-52
104. **Lordick F**, Janjigian YY. Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol. 2016 Jun;13(6):348-60
105. Moehler M, Delic M, Goepfert K, Aust D, Grabsch HI, Halama N, Heinrich B, Julie C, **Lordick F**, Lutz MP, Mauer M, Alsina Maqueda M, Schild H, Schimanski CC, Wagner AD, Roth A, Ducreux M. Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. Eur J Cancer. 2016;59:160-70
106. Obermannová R, **Lordick F**. Insights into next developments in advanced gastric cancer. Curr Opin Oncol. 2016 Jul;28(4):367-75
107. Ochsenreither S, **Lordick F**. New concepts for clinical trial design in oncology. Forum 2016; 31: 221-225
108. van Oorschot B, Ruellan A, **Lordick F**. für die Arbeitsgemeinschaft Palliativmedizin der Deutschen Krebsgesellschaft (APM). Choosing wisely – Klug entscheiden bei Tumorpatienten mit limitierter Prognose. Forum 2016; 31: 237–240
109. Lorenzen S, **Lordick F**. Fortgeschrittenes Magenkarzinom Status quo der systemischen Therapie und Einfluss auf die Lebensqualität. Onkologie 2016; 22:406–412
110. Lutz MP, Zalcborg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, **Lordick F**, Mentha G, Moehler M, Nagtegaal ID, Pigazzi A, Puciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E, Weitz J, Otto F. Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. Eur J Cancer 2016 May 30;63:11-24
111. Baretton G, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Röcken C, Rüschoff J, Tannapfel A, **Lordick F**, Al-Batran S, Hofheinz R, Lorenzen S, Moehler M, Thuss-Patience P. [HER2 testing in gastric cancer : Results of a meeting of German experts]. Pathologe. 2016 Jul;37(4):361-6
112. **Lordick F**, Al-Batran SE, Hofheinz RD, Lorenzen S, Thuss-Patience P, Baretton GB, Dietel M, Gaiser T, Kirchner T, Kreipe HH, Quaas A, Röcken C, Rüschoff J, Tannapfel A. [HER2 testing in gastric cancer - results of a German expert meeting]. Z Gastroenterol. 2016 Aug;54(8):791-6. doi:10.1055/s-0042-110794. Epub

2016 Aug 16. German. PubMed PMID: 27529529.

113. **Lordick F**, Mariette C, Haustermans K, Obermannová R, Arnold D; ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2016 Sep;27(suppl 5):v50-v57
114. Van Laethem JL, Carneiro F, Ducreux M, Messman H, **Lordick F**, Ilson DH, Allum WH, Haustermans K, Lepage C, Matysiak-Budnik T, Cats A, Schmiegel W, Cervantes A, Van Cutsem E, Rougier P, Seufferlein T. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. *Dig Liver Dis*. 2016 Nov;48(11):1283-1289.
115. **Lordick F**, Terashima M. Gastric cancer adjuvant therapy. *Best Pract Res Clin Gastroenterol*. 2016 Aug;30(4):581-91
116. Klar E, Büchler MW, Lang H, **Lordick F**, Mittler J, Mizuno T, Torzilli G, Ulrich A, Vauthey JN. Oligometastases of Gastrointestinal Cancer Origin. *Visc Med* 2017; 33: 76-81
117. **Lordick F**. Anti-angiogenesis: disappointment in localised oesophagogastric cancer. *Lancet Oncol*. 2017 Mar;18(3):278-279. doi: 10.1016/S1470-2045(17)30029-3. PubMed PMID: 28163003
118. **Lordick F**. [Novel pharmaceutical treatment approaches for gastric cancer]. *Pathologe*. 2017 Mar;38(2):87-92. doi: 10.1007/s00292-017-0272-2. German. PubMed PMID: 28220199.
119. **Lordick F**, Al-Batran SE, Dietel M, Gaiser T, Hofheinz RD, Kirchner T, Kreipe HH, Lorenzen S, Möhler M, Quaas A, Röcken C, Rüschoff J, Tannapfel A, Thuss-Patience P, Baretton G. HER2 testing in gastric cancer: results of a German expert meeting. *J Cancer Res Clin Oncol*. 2017 143(5), 835-841; doi: 10.1007/s00432-017-2374-x.
120. **Lordick F**. Anti-angiogenesis: disappointment in localised oesophagogastric cancer. *Lancet Oncol*. 2017 Mar;18(3):278-279.
121. **Lordick F**, Mössner J. [Current Standard Diagnosis and Treatment of Colon Cancer]. *Dtsch Med Wochenschr*. 2017 Apr;142(7):487-490.
122. **Lordick F**, Hacker U. Weight loss in cancer patients. *Aktuel Ernährungsmed* 2017; 42: 115-122
123. **Lordick F**. Salvage chemotherapy for advanced gastric cancer: more than a false hope? *Lancet Gastroenterol Hepatol*. 2017 Apr;2(4):240-241.
124. Obermannová R, **Lordick F**. Management of Metastatic Gastric Cancer. *Hematol Oncol Clin North Am*. 2017 Jun;31(3):469-483
125. Lutz MP, Zalberg JR, Ducreux M, Aust D, Bruno MJ, Büchler MW, Delpero JR, Gloor B, Glynne-Jones R, Hartwig W, Huguet F, Laurent-Puig P, **Lordick F**, Maisonneuve P, Mayerle J, Martignoni M, Neoptolemos J, Rhim AD, Schmiegel BM, Seufferlein T, Werner J, van Laethem JL, Otto F. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial

issues in the primary treatment of pancreatic cancer. *Eur J Cancer*. 2017 Apr 28;79:41-49

126. Keck Chair T, Herrlinger Chair KR, Faiss S, **Lordick F**, Mansky T, Welsch T. Arguments for and against Centralization in Oncologic Visceral Medicine. *Visc Med*. 2017 May;33(2):148-152.
127. Klar E, Büchler MW, Lang H, **Lordick F**, Mittler J, Mizuno T, Torzilli G, Ulrich A, Vauthey JN. Oligometastases of Gastrointestinal Cancer Origin. *Visc Med*. 2017 Mar;33(1):76-81.
128. Smyth EC, Lagergren J, Fitzgerald RC, **Lordick F**, Shah MA, Lagergren P, Cunningham D. Oesophageal cancer. *Nat Rev Dis Primers*. 2017 Jul 27;3:17048.
129. Mehnert A, **Lordick F**. [Cancer Throughout the Lifespan - Addressing the Psychosocial Needs of Diverse Populations]. *Psychother Psychosom Med Psychol*. 2017 Jul;67(7):277-278.
130. **Lordick F**, Shitara K, Janjigian YY. New Agents on the Horizon in Gastric Cancer. *Ann Oncol*. 2017 28: 1767–1775
131. Kataoka K, Deleersnijder A, **Lordick F**. Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer? *Eur J Surg Oncol*. 2017 Oct;43(10):1835-1845
132. Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, **Lordick F**, Reni M. What treatment in 2017 for inoperable pancreatic cancers? *Ann Oncol*. 2017 Jul 1;28(7):1473-1483
133. Segelov E, **Lordick F**, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australian gastrointestinal trials group with invited international faculty. *Expert Rev Anticancer Ther*. 2017 Aug 28:1-14
134. **Lordick F**. Treatment of oesophageal cancer - Stressing the patient perspective. *Eur J Canc* 2017; 84: 360-362
135. **Lordick F**. Changing paradigms in adjuvant treatment of colorectal cancer. *Lancet Gastroenterol Hepatol*. 2018 Jan;3(1):6-8.
136. Allum W, **Lordick F**, Alsina M, Andritsch E, Ba-Ssalamah A, Beishon M, Braga M, Caballero C, Carneiro F, Cassinello F, Dekker JW, Delgado-Bolton R, Haustermans K, Henning G, Hutter B, Lövey J, Netíková IŠ, Obermannová R, Oberst S, Rostoft S, Saarto T, Seufferlein T, Sheth S, Wynter-Blyth V, Costa A, Naredi P. ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. *Crit Rev Oncol Hematol*. 2018 Feb;122:179-193
137. **Lordick F**. Response-adapted treatment stratification in oesophago-gastric cancer. *Eur J Cancer*. 2018 Mar;92 Suppl 2:S3.
138. **Lordick F**. More is more? Pushing chemoradiotherapy of oesophageal squamous cell carcinoma forward. *Eur J Cancer*. 2018 Jul;97:25-26. doi: 10.1016/j.ejca.2018.03.028.

139. Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27. Rinke A, Wiedenmann B, Auernhammer C, Bartenstein P, Bartsch DK, Begum N, Faiss S, Fottner C, Gebauer B, Goretzki P, Lynen Jansen P, Pöppel G, Scherübl H, Weber MM, Gress TM, Pavel M, Albert J, Alfke H, Amthauer H, Anlauf M, Arnold R, Baum R, Denecke T, Ezziddin S, Fendrich V, Gniffke S, Haug A, Hörsch D, Kegel T, Knoefel WT, Knösel T, Kratochwil C, Lahner H, **Lordick F**, Luster M, Mahnken A, Mellar K, Mönig H, Musholt TJ, Nothacker M, Pape UF, Pascher A, Pöppel T, Prasad V, Probst A, Scheidhauer K, Schneider D, Schott M, Schrader J, Seufferlein T, Sipos B, Spitzweg C, Steinmüller T, Trumm C, Wurst C, Zorger N. *Z Gastroenterol.* 2018 Jun;56(6):583-681. doi: 10.1055/a-0604-2924
140. Adenis A, **Lordick F**. Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer. 2018 Jun 1;4(6):887-888
141. Aggelis V, Cunningham D, **Lordick F**, Smyth EC. Peri-operative therapy for operable gastroesophageal adenocarcinoma; past, present and future. 2018 Jun 1;29(6):1377-1385
142. Rinke A, Wiedenmann B, Auernhammer C, Bartenstein P, Bartsch DK, Begum N, Faiss S, Fottner C, Gebauer B, Goretzki P, Lynen Jansen P(9), Pöppel G, Scherübl H, Weber MM, Gress TM, Pavel M, Albert J, Alfke H, Amthauer H, Anlauf M, Arnold R, Baum R, Denecke T, Ezziddin S, Fendrich V, Gniffke S, Haug A, Hörsch D, Kegel T, Knoefel WT, Knösel T, Kratochwil C, Lahner H, **Lordick F**, Luster M, Mahnken A, Mellar K, Mönig H, Musholt TJ, Nothacker M, Pape UF, Pascher A, Pöppel T, Prasad V, Probst A, Scheidhauer K, Schneider D, Schott M, Schrader J, Seufferlein T, Sipos B, Spitzweg C, Steinmüller T, Trumm C, Wurst C, Zorger N Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS); Netzwerk Neuroendokrine Tumoren (NeT) e.V. (Patientenvertretung); Bundesorganisation Selbsthilfe NeuroEndokrine Tumoren e.V. (NET-sgh) (Patientenvertretung); Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. (DGHO), und Arbeitsgemeinschaft Internistische Onkologie (AIO) der Deutschen Krebsgesellschaft e.V; Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie e.V. (DGAV); Deutsche Gesellschaft für Chirurgie (DGCH); Deutsche Gesellschaft für Endoskopie und Bildgebende Verfahren (DGEbV); Deutsche Gesellschaft für Nuklearmedizin e.V. (DGNM); Deutsche Gesellschaft für Innere Medizin (DGIM); Deutsche Gesellschaft für Endokrinologie (DGE); Deutsche Gesellschaft für Palliativmedizin e.V. (DGP); Deutsche Röntgengesellschaft e.V. (DRG); Deutsche Gesellschaft für Pathologie e.V./Bundesverband Deutscher Pathologen (DGP/BDP); Deutsche Gesellschaft für interventionelle Radiologie (DGIR); Authors; Collaborators: [Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27]. *Z Gastroenterol.* 2018 Jun;56(6):583-681
143. Pfirrmann D, Simon P, Mehdorn M, Hänsig M, Stehr S, Selig L, Weimann A, Knödler M, **Lordick F**, Mehnert A, Gockel I. [Preconditioning prior to visceral oncological surgery : A paradigm shift in visceral surgery?]. *Chirurg.* 2018 Nov;89(11):896-902
144. Piegeler T, Stehr SN, Pfirrmann D, Knödler M, **Lordick F**, Mehnert A, Selig L, Weimann A, Mehdorn M, Gockel I, Simon P. [Special situations of preconditioning and prehabilitation in oncological visceral surgery]. *Chirurg.* 2018 Nov;89(11):903-908.

145. Ilson D, **Lordick F**. Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer? *Lancet Oncol* 2018; 19 (10): 1285–1286
146. **Lordick F**, Röcken C. Molekulares Tumorboard. Magenkarzinom. Prädiktoren der Immuntherapie. *FORUM* 2018 · 33:405–410
147. **Lordick F**. Towards risk-adapted perioperative treatment of gastroesophageal cancer. *Ann Oncol*. 2018 Dec 1;29(12):2282-2284
148. Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, **Lordick F**, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. *Ann Oncol*. 2019 Jan 1;30(1):19-33
149. Muro K, **Lordick F**, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino T, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. *Ann Oncol*. 2019 Jan 1;30(1):34-43
150. **Lordick F**, Smyth EC. Two steps forward and one step back. *Nat Rev Clin Oncol*. 2019 Feb;16(2):69-70
151. Lutz MP, Zalcborg JR, Ducreux M, Adenis A, Allum W, Aust D, Carneiro F, Grabsch HI, Laurent-Puig P, **Lordick F**, Möhler M, Mönig S, Obermannova R, Piessen G, Riddell A, Röcken C, Roviello F, Schneider PM, Seewald S, Smyth E, van Cutsem E, Verheij M, Wagner AD, Otto F. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. *Eur J Cancer*. 2019 Mar 14; 112: 1-8.
152. Fries H, Hitzschke M, **Lordick F**. A Different Kind of Relapse: Ethanol as an Additive in Chemotherapy Formulations. *Oncol Res Treat*. 2019 Apr 17:1-4
153. De Mello RA, **Lordick F**, Muro K, Janjigian YY. Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. *Am Soc Clin Oncol Educ Book*. 2019 Jan;(39): 237-247

Case reports in peer-reviewed journals

1. Apostolidis L, Kahlert C, Siegmund A, Thom R, Horstmann S, Jäger D, **Lordick F**. Remission of Paraneoplastic Dermatomyositis Associated with Hepatocellular Carcinoma under Prednisolone and Azathiopin, and Concomittant Sorafenib. *Onkologie*. 2009; 32: 50-53.
2. Berger AK, Bellos F, Siegmund A, Eisenbach C, **Lordick F**. Symptomatic hyponatraemia caused by cylophosphamide. *Onkologie*. 2009; 32: 280-282.
3. Cella CA, Carlomagno C, **Lordick F**, Moretto R, De Stefano A, Raimondo L, D'Armiento M, Camera L, Guadagno E, Attademo L, Feliciano S, Matano E. Basaloid Squamous Cell Carcinoma: A Rare Tumor at the Esophagogastric Junction and an Unexpected Durable Complete Response to FOLFOX-4. *Oncol Res Treat*. 2014;37(1-2):55-8
4. Golombek T, Henker R, Rehak M, Quäschling U, Lordick F, Knödler M. A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin. *Oncol Res Treat*. 2019;42(3):123-127

Book Chapters and Book Editorship

1. Gündel H, **Lordick F**, Mert E, von Schilling C, Würschmidt F, Sellschopp A. Psychoedukative Patientengruppen – Angloamerikanische Konzepte und ihre Umsetzung in Deutschland. In: Empfehlungen zur Diagnostik, Therapie und Nachsorge Psychoonkologie. Tumorzentrum München (Hrsg.). 1. Auflage 2002. W. Zuckschwerdt Verlag München, Bern, Wien, New York.
2. Müller Ch, Strauss T, Zimmermann F, **Lordick F**, Schalhorn A. Pleuratumoren/malignes Mesotheliom: Klinik, Diagnostik und Therapie. In: Manual des Tumorzentrums München. 6. überarbeitete Auflage 2003. Zuckschwerdt Verlag München Wien New York.
3. **Lordick F**, Siewert JR. The Role of Induction Chemotherapy in Upper GI Cancer. Proceedings of the 11th European United Gastroenterology Week 2003, Madrid, Spain.
4. Zimmermann F, Meining A, **Lordick F**, Sarbia M, Brücher B. Ösophagus-Plattenepithelkarzinom. In Manual des Tumorzentrums München, 7. Auflage 2006, Zuckschwerdt Verlag München.
5. Sendler A, Prinz C, Janetschek P, Becker K, Grützner U, **Lordick F**, Schuhmacher C, Zimmermann F. Magenkarzinom. In Manual des Tumorzentrums München, 7. Auflage 2006, Zuckschwerdt Verlag München.
6. Peschel C, **Lordick F** (Hrsg.). Therapie-induzierte Nausea und Emesis in der Onkologie. 1. Auflage 2006, Uni-Med Verlag Bremen, London, Boston.
7. Siewert JR, Stein HJ, **Lordick F**. Ösophaguskarzinom. In: Siewert JR, Rothmund M, Schumpelick V (eds). Praxis der Viszeralchirurgie: Onkologische Chirurgie, 2. Auflage. Berlin, Heidelberg, New York: Springer Verlag; Kapitel 35, S. 445-81
8. Siewert JR, Sendler A, **Lordick F**. Magenkarzinom. In: Siewert JR, Rothmund M, Schumpelick V (eds). Praxis der Viszeralchirurgie: Onkologische Chirurgie, 2. Auflage 2006. Berlin, Heidelberg, New York: Springer Verlag; Kapitel 35, S. 403-33
9. Siewert JR, **Lordick F**. Standards in der interdisziplinären Diagnostik und Therapie. In: Kompendium Internistische Onkologie (Hrsg.: Schmoll, Höffken, Possinger), 4. Auflage 2006. Springer Verlag, Heidelberg, Berlin, New York.
10. Zimmermann F, Meining A, **Lordick F**, Sarbia M, Brücher B. Ösophagus-Plattenepithelkarzinom. In: Sendler A (ed). Manual Gastrointestinale Tumoren des Tumorzentrum München. Empfehlungen zur Diagnostik, Therapie und Nachsorge. München: Zuckschwerdt-Verlag; S. 1-18
11. Sendler A, Prinz C, Janetschek P, Becker K, Grützner U, **Lordick F**, Schuhmacher C, Zimmermann F (2006) Magenkarzinom. In: Sendler A (ed). Manual Gastrointestinale Tumoren des Tumorzentrum München. Empfehlungen zur Diagnostik, Therapie und Nachsorge. München: Zuckschwerdt-Verlag; S. 26-53
12. **Lordick F**, Sendler A. Magenkarzinom. In: Diagnostik und Therapie gastrointestinaler Tumoren (Hrsg. Illiger und Schmoll). Uni-Med Verlag AG Bremen – London – Boston; in press

13. Nieder C, **Lordick F**. Combination of platinum compounds and ionizing radiation: In: Brown JM, Mehta MP, Nieder C. Multimodal Concepts for Integration of Cytotoxic Drugs and Radiation Therapy. Springer Berlin, Heidelberg, New York 2006, 1. Auflage.
14. Siewert JR, Molls M, Zimmermann F, **Lordick F**. Esophageal Cancer – Clinical Management. In: Kelsen DP, Daly JM, Kern SE, Levin B, Tepper JE. Gastrointestinal Oncology. Principles and Practice. Lippincott Williams & Wilkins, Philadelphia 2007; 2nd edition.
15. Sendler A, **Lordick F**, Tannapfel A. Das Magenkarzinom. In: Hiddemann W (Hsg.) Onkologie, Springer Berlin, Heidelberg, New York, 2007; 2. Auflage.
16. **Lordick F**. Therapiestrategien bei Patienten mit synchron metastasierten kolorektalen Karzinomen. In Bokemeyer (Hrsg.): Das kolorektale Karzinom – Grundlagen, Prävention und moderne Therapiekonzepte. SocioMed Verlag 2007; 1. Auflage.
17. **Lordick F**, Sendler A. Magenkarzinom. In: Therapiekonzepte bei gastrointestinalen Tumoren. Hrsg. Schmoll & Arnold, Uni-Med Verlag, Bremen, 2009. 1. Auflage.
18. Siewert JR (Herausgeber), **Lordick F** (Redaktion). Praxis der Viszeralchirurgie – Onkologische Chirurgie. Springer Verlag Heidelberg Berlin New York 2010, 3. Auflage. ISBN 978-3-642-03807-5
19. **Lordick F**. Biologisch zielgerichtete Therapie. In Siewert JR, Lordick F: Praxis der Viszeralchirurgie – Onkologische Chirurgie. Springer Verlag Heidelberg Berlin New York, 2010, 3. Auflage. ISBN 978-3-642-03807-5
20. **Lordick F**, Beiglböck A, Jäger D, Siewert JR. Multidisziplinarität im Cancer Center. In Siewert JR, Lordick F: Praxis der Viszeralchirurgie – Onkologische Chirurgie. Springer Verlag Heidelberg Berlin New York, 2010, 3. Auflage. ISBN 978-3-642-03807-5
21. **Lordick F**, Hölscher AH. Esophageal Cancer. In: Blanke, Roedel, Talamonti: Gastrointestinal Oncology, a Practical Guide. Springer Heidelberg Berlin New York, 2010, 1. Edition, ISBN Nummer 978-3-642-13305-3
22. **Lordick F (Herausgeber)**: Biologie und zielgerichtete Therapie des Magenkarzinoms. 1. Auflage 2011; Uni-Med Verlag AG Bremen – London – Boston
23. **Lordick F**, Peschel V (**Herausgeber**): Therapie-induzierte Nausea und Emesis in der Onkologie. 3. Auflage 2011; Uni-Med Verlag AG Bremen – London – Boston
24. **Lordick F**, Hacker U (Herausgeber): Zielgerichtete Therapie des kolorektalen Karzinoms. 1. Auflage 2013 Uni-Med Verlag AG Bremen, International Publishers (London, Boston)
25. **Lordick F**, Lorenzen S (Herausgeber): Nausea und Emesis in der Onkologie. 1. Auflage 2014, Uni-Med Verlag AG, Bremen, London, Boston. ISBN 978-3-8374-2321-1
26. **Lordick F**, Hacker U. Chemotherapy and Targeted Therapy. In: Medical Radiology, Diagnostic Imaging: Imaging Complications and Toxicity following Tumor Therapy 2015. Springer Berlin Heidelberg: ISBN 978-3-319-12840-5; doi 10.1007/174_2014_1040

27. Ott K, **Lordick F**, Siewert JR. Oesophageal Cancer: Treatment Strategies. In: Kuzdzal J. Textbook of Thoracic Surgery, Volume 2. Medycina Praktyczna, Liszi, ISBN 978-83-7430-331-6; 591-600
28. **Lordick F**: Supportive Tumortherapien. In: Erckenbrecht JF, Jonas S (Hrsg.), Viszeralmedizin, Springer-Verlag Berlin Heidelberg 2015, S. 440 – 445
29. Bahra M, **Lordick F**, Lutz M, Glanemann M, Neuhaus P: Pankreaskarzinom. In: Erckenbrecht JF, Jonas S (Hrsg.), Viszeralmedizin, Springer-Verlag Berlin Heidelberg 2015, S. 557 – 567
30. **Lordick F**. (Herausgeber) Biologie und zielgerichtete Therapie des Magenkarzinoms. Uni-med Verlag Bremen, London, Boston. 2. Auflage, 2015
31. **Lordick F**. Perspektiven in der Onkologie. In: Alt-Epping B, Fuxius S, Wedding U (Hg.). Onkologie für die Palliativmedizin. Universitätsverlag Göttingen 2015, ISBN: 978-3-86395-229-7; Seite 225-232
32. **Lordick F**. Zielgerichtete medikamentöse Therapie. In Mehnert A, Koch U. Handbuch Psychoonkologie. Holzgreve Verlag GmbH Göttingen, 2016, 1. Auflage, ISBN 978-3-8017-2474-0; Seite 42-52
33. Editors: Prof. Dr. Irenäus A. Adamietz, Prof. Dr. Wolf O. Bechstein, Prof. Dr. Hans Christiansen, Prof. Dr. Christian Doehn, Prof. Dr. Andreas Hochhaus, Prof. Dr. Ralf-Dieter Hofheinz, Prof. Dr. Werner Lichtenegger, **Prof. Dr. Florian Lordick**, Prof. Dr. Dirk Schadendorf, Prof. Dr. Michael Untch, Prof. Dr. Christian Wittekind. Weiterbildung Onkologie. Springer, Berlin, New York, Heidelberg. ISBN: 978-3-662-49414-1 (Print) 978-3-662-49415-8 (Online)
34. Lorenzen S, **Lordick F**. Nausea und Emesis in der Onkologie. 2. Auflage, 2016. UniMed Verlag AG, Bremen-London-Boston (2016 noch nicht gemeldet!)
35. Hacker U, **Lordick F**. Anti-Angiogenics in Gastroesophageal Cancer. In D. Marmé (ed.), Tumor Angiogenesis. Springer International Publishing AG 2017. DOI 10.1007/978-3-319-31215-6_17-1, page 1-19
36. **Lordick F**, Hacker U. Zielgerichtete Therapie des kolorektalen Karzinoms. 2. Auflage, 2017. UniMed Verlag AG, Bremen-London-Boston
37. **Lordick, F.**: Kapitel 16 – Onkologische Tumortherapie in 20 Jahren. S. 141-144. In: Alt-Epping, B.; Fuxius, S; Wedding, U.: Elsevier Essentials Onkologie. Elsevier GmbH, München. 2017; ISBN 3-437-21431-8.
38. Stocker G, **Lordick F**. Infektionen und Entzündungsreaktionen als Folge der Tumorbehandlung. S 425-434. In: Lübbert C, Vogelmann R (Hrsg.) Gastroenterologische Infektiologie. De Gruyter Verlag, Berlin, 2017. ISBN 978-3-11-040427-2
39. Behrens A, **Lordick F**. Ösophagustumoren. S. 100-110. In: Layer P, Rosien U (Hrsg.) Facharztwissen Gastroenterologie. Elsevier Verlag, München, 1. Auflage 2017; ISBN 978-3-437-21251-2
40. Behrens A, **Lordick F**. Magenkarzinom. S. 134-139. In: Layer P, Rosien U (Hrsg.) Facharztwissen Gastroenterologie. Elsevier Verlag, München, 1. Auflage 2017; ISBN 978-3-437-21251-2

41. Golombek T, **Lordick F**. Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung. In: B Rau, P Piso, A Königsrainer (Hrsg.): Peritoneale Tumoren und Metastasen. Springer Verlag GmbH Deutschland 2018: http://doi.org/10.1007/978-3-662-54500-3_26. ISBN 978-3-662-54499-0
42. **Lordick F**, Gockel I, Mössner J. Ösophaguskarzinom beim alten und geriatrischen Patienten. In: Ebert M, Härtel N, Wedding U. Geriatrische Onkologie, Springer Nature 2018, ISBN 978-3-662-48726-6; S. 313-324
43. **Lordick F**. Immunonkologie der soliden Tumoren – Neues. In: Petrasch S, Ehninger G. Colloquium Onkologie 24. Update Hämatologie / Onkologie 2017. Lukon Verlag München 2018; S.31-40; ISBN 978-3-933012-38-8

Leipzig, 26th May 2019



Prof. Dr. Florian Lordick